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Background: Dyslipidemia is one of the most perplexing metabolic consequences in polycystic ovary syndrome (PCOS). 
Obesity, insulin resistance (IR), and hyperandrogenism, the pervasive features of PCOS, play significant pathophysiological 
roles in the lipidemic aberrations associated with the syndrome.
Objective: This study aimed to assess the diagnostic utility of triglyceride (TG) and triglyceride to high‑density 
lipoprotein‑cholesterol (TG/HDL‑C) ratio as surrogate markers for identifying IR in infertile Nigerian women with PCOS.
Materials and Methods: Eighty‑seven infertile women with PCOS were selected according to the Androgen Excess Society 
criteria and categorized into two groups. After anthropometric measurements, fasting blood samples were assayed for plasma 
glucose, serum insulin, total cholesterol, TG, HDL‑C while lipoprotein ratios were calculated. Homeostasis model assessment 
for IR (HOMA‑IR) was used in defining IR. The areas under the receiver operating characteristic (ROC) curve analysis were 
used to compare the power of the serum markers, and to obtain the optimal cutoffs of TG and TG/HDL‑C with HOMA‑IR.
Results: TGs correlated significantly with HOMA‑IR in the obese PCOS women. However, the areas under the ROC of 
potential markers showed no significant marker for HOMA‑IR. The highest area under the curve of ROC for TG belongs to 
the obese group with a sensitivity of 56% and specificity of 53% (TG ≥ 92.5mg/dL) as a marker of IR in obese PCOS women.
Conclusion: TG and TG/HDL‑C would not be reliable markers of IR, and a concerted approach in finding surrogate markers 
will benefit future investigations.
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Introduction
Dyslipidemia, common in polycystic ovary syndrome (PCOS) 
has multifactorial causation.[1] Women with PCOS are 
frequently found to have atherogenic lipid abnormalities that 
may reflect underlying insulin resistance (IR).[2] IR plays a pivotal 
role by the stimulation of lipolysis and altered expression of 
lipoprotein lipase and hepatic lipase.[1] At the heart of the 
pathophysiology of PCOS is IR and hyperinsulinemia, and 
it may also lead to hyperglycemia and adverse profiles of 
cardiovascular risk factors. Although the links between IR and 
associated dyslipidemia, hypertension, and atherosclerosis 
are complex, dysregulation of fatty acid metabolism seems 
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central to the pathophysiology of the IR syndrome, as it is 
related to cardiovascular disease.[3] Dyslipidemia in PCOS is 
characterized by higher TGs and lower high-density lipoprotein 
cholesterol (HDL-C). IR occurs in about 50–80% of women with 
PCOS.[1] In the insulin-resistant state, non-esterified fatty acids 
are mobilized from the muscle and adipose tissues to the liver, 
thereby increasing the substrate for TGs production.[4] The 
gold standard methods designed to measure insulin sensitivity 
are impracticable in the clinical setting since they can only 
be performed in specialized centers due to being complex, 
expensive, and time-consuming.[5] Likewise, other surrogate 
markers based on fasting insulin and glucose levels present 
important limitations related to their poor reproducibility 
and reliability. Besides, no clear guidelines and no universally 
accepted cutoffs are available for most of the main surrogate 
markers used.[6-8] Some studies have reported that TGs and 
the TGs/HDL-C ratio were closely and positively related to 
IR, and the two variables were recommended as surrogates 
for IR.[9-15] In contrast, some other studies showed that TG 
and TG/HDL-C ratio were not reliable markers of IR in some 
populations.[16-18] In developing countries, the cost of insulin 
assay can be a major limitation in the assessment of IR. 
Therefore, the utilization of surrogate markers like TG which 
is feasible in small centers, lower in costs, and applies to the 
general population can be a useful alternative. The present 
study aimed to assess the diagnostic utility of TG and TG/
HDL-C ratio as surrogate markers in identifying IR in Nigerian 
women with PCOS.
Patients and Methods
This study selected 87 women with PCOS attending Infertility 
Clinics at the…. between April 1, 2009, and November 30, 
2010. The diagnoses of PCOS were according to the Androgen 
Excess-PCOS Society (AES) criteria which are specifically 
defined by the presence of hyperandrogenism (clinical and/or 
biochemical), ovarian dysfunction (oligo-anovulation and/or 
polycystic ovaries), and the exclusion of related disorders.[19] 
For the AE-PCOS Society, the definition was analogous to the 
Rotterdam criteria but excluded women with only menstrual 
dysfunction and polycystic ovaries. Inclusion criteria were 
women with clinical and/or biochemical hyperandrogenism, 
ovulatory dysfunction, and/or polycystic ovaries detected 
by ultrasound scans. Exclusion criteria were women with 
hyperprolactinemia, congenital adrenal hyperplasia, thyroid 
dysfunction, on hormonal therapy or medications that could 
influence the hormonal assay. Fully informed consent was 
obtained from all the women. A pre-prepared standard pro 
forma was used in capturing the data on age, clinical and 
medical history, detailed anthropometry, and blood pressure 
measurements. Body mass index (BMI) was calculated as 
weight (kg)/height (m2).
After an overnight fast, blood samples were drawn 
from the antecubital vein. The fasting blood samples 
were analyzed for baseline metabolic profiles namely, 
fasting plasma glucose (FG), serum total cholesterol (TC), 
TGs (TG), HDL-C, total testosterone (TT), luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), 
prolactin (PRL), thyroid-stimulating hormone (TSH), 17 
hydroxyprogesterone (17-OHProg), insulin, uric acid, and 
high sensitivity C-reactive protein (hs-CRP). Low-density 
lipoprotein-cholesterol (LDL-C) was calculated using 
Friedewald’s formula.[20] Uric acid was measured using the 
enzymatic method with the Randox kit (RANDOX, USA). All 
hormones and hs-CRP were measured using the enzyme-linked 
immunosorbent assay (ELISA) method with DRG kits (Marburg, 
Germany. Version 8.0). The detailed method has been 
published elsewhere.[21,22] IR was defined by using HOMA-IR, 
which was calculated as (fasting glucose mg/dL × fasting 
insulin µU/mL)/22.5.
Statistical analysis
Statistical analysis was performed using IBM Statistical 
Package for the Social Sciences (SPSS) Version 21.0, for 
Windows (SPSS, Inc., Chicago IL, USA). The mean ± standard 
deviation of the quantitative measurements is presented. 
Data for TT, LH/FSH ratio, fasting insulin (FI), HOMA-IR, fasting 
glucose to fasting insulin (FG/FI) ratio, hs-CRP, and uric acid 
were skewed, and are presented as median (interquartile 
range), and were log-transformed for analysis. The split data 
procedure was used to divide the subjects into two groups 
using	 their	 BMI	 characteristics;	 obese	≥	25.0	 kg/m2 and 
nonobese < 25.0kg/m2. The differences between the obese 
and nonobese groups were determined using independent 
sample student t-test and Chi-square test—χ2.
The areas under the receiver operating characteristic (ROC) 
curves were used to compare the power of the serum markers. 
The standard errors of each characteristic were presented 
with the areas under the ROC curves. The sensitivity and 
specificity values for TG were also derived using the point 
of inflection from the areas under the ROC curve. Likelihood 
ratios (LR) were calculated as the ratios of sensitivity/
(1	−	specificity)	for	positive	LR	and	(1	−	sensitivity)/specificity	




Where TP is true positive, TN is true negative, FP is false 
positive, and FN is false negative.
Multiple linear regression analysis was used to evaluate 
the contribution of each confounding factor for HOMA-IR. 
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Two-tailed P values of < 0.05 were considered to be 
statistically significant all through this study.
Ethical consideration
The ethics and research committee of the…. approved 
the study proposal and issued the clearance certificate. 
Fully informed consent was obtained from all women who 
participated in the study.
Results
The PCOS women were categorized into two groups: 
nonobese (BMI < 25.0 kg/m2)	and	obese	(BMI	≥	25.0	kg/m2), 
with their clinical and biochemical characteristics given 
in Table 1. The nonobese women were 30 with a mean 
BMI of 23.22 ± 1.16 kg/m2 and obese women were 57 
with a mean BMI of 28.83 ± 3.23 kg/m2. The mean ages 
of nonobese and obese women were 28.2 ± 5.62 years 
and 33.35 ± 4.86 years, respectively. The mean weight 
of nonobese women was 60.69 ± 5.25 kg and the mean 
weight of the obese group was 75.99 ± 10.82 kg. Data 
on some of the variables were significantly different 
between the nonobese and the obese groups namely age, 
weight, BMI, systolic blood pressure (SBP), diastolic blood 
pressure (DBP), mean blood pressure (MBP), mean arterial 
blood pressure (MABP), TT, LH/FSH ratio, hs-CRP, and uric 
acid. After adjustment of age [Table 1], the weight, BMI, SBP, 
and MABP remained similarly significant in nonobese and 
obese	groups,	while	the	prevalence	of	 IR	(HOMA‑IR	≥	2)	
was significantly higher in the nonobese group than the 
obese group.
Nonobese and obese women were comparable in terms of 
the mean values of serum total cholesterol, HDL-C, LDL-C, 
total cholesterol to HDL-C (TC/HDL-C) ratio, and LDL-C/HDL-C 
ratios (P > 0.05) [Table 2]. However, the serum TG and the 
TG/HDL-C ratio showed a significant difference between the 
nonobese and the obese groups. The mean values of the 
lipid profile variables were comparable in both nonobese and 
obese groups after adjustment of age (P > 0.05).
T h e  a r e a s  u n d e r  t h e  R O C  c u r v e s  a n a l y s e s 
[Table 3, Figures 1a and 1b] performed on the data of some 
variables for both obese and nonobese groups demonstrated 
that there was no statistically significant marker for IR among 
the potential markers. In the nonobese group, TG and 
hs-CRP had areas under the ROC curve of 0.569 and 0.608, 
respectively, and in obese group areas under the ROC curve of 
0.540 and 0.594, respectively. However, they did not exhibit 
statistical significance.
In the obese group [Figure 2], TG had a significant association 
with HOMA-IR (R2 = 0.112, P < 0.00) but not with the 
nonobese group (R2 = 0.014, P > 0.05). When multiple linear 
regression analysis was used to investigate the effect of various 
Table 1: Characteristics of subjects categorized by BMI
Characteristics Total n=87 Nonobese (<25.0 kg/m2) n=30 Obese (≥25.0 kg/m2) n=57 P* Age-adjusted P+
Age (years) 31.57±5.66 28.2±5.62 33.35±4.86 <0.001 ‑
Weight (kg) 70.72±11.79 60.69±5.25 75.99±10.82 <0.001 <0.001
Height (m) 1.62±0.060 1.62±0.065 1.62±0.058 0.673 0.669
BMI (kg/m2) 26.89±3.80 23.22±1.16 28.83±3.23 <0.001 <0.001
SBP (mmHg) 119.43±14.25 112.00±9.61 123.00±14.8 <0.001 <0.001
DBP (mmHg) 77.47±11.12 73.00±9.52 79.82±11.26 <0.001 0.126
MBP (mmHg) 116.82±14.35 110.00 ± 120.00±14.67 <0.001 0.110
MABP (mmHg) 91.46±11.20 86.00±8.32 94.33±11.51 <0.001 <0.001
TT (ng/mL) 1.61±1.57 2.09±2.22 1.36±0.96 <0.001 0.077
LH/FSH 2.67±2.97 3.53±4.15 2.21±2.01 <0.001 0.964
FG (mg/dL) 80.69±16.21 76.30±9.60 83.00±18.44 0.067 0.257
OGTT (mg/dL) 96.60±29.31 91.73±19.46 99.16±33.22 0.264 0.633
FI (µU/mL) 10.00±10.76 10.64±9.10 2.05±2.69 0.693 0.413
FG/FI 18.12±23.8 13.31±12.85 20.65±27.66 0.173 0.291
hs‑CRP (mg/L) 9.76±8.23 6.72±3.72 11.36±9.45 0.018 0.077
Uric acid (mg/dL) 5.47±1.71 4.79±1.04 5.83±1.90 0.006 0.118
HOMA‑IR 2.07±2.44 2.12±1.92 2.05±2.69 0.907 0.517
HOMA‑IR < 2 (%) 58 (66.7) 19 (63.3) 39 (68.4) 0.632 0.002
HOMA‑IR ≥ 2 (%) 29 (33.3) 11 (36.7) 18 (31.6) 0.510 0.032
BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; MBP: mean blood pressure; MABP: mean arterial blood pressure; TT: total testosterone; LH/
FSH: luteinizing hormone to follicle‑stimulating hormone ratio; FG: fasting glucose; OGTT: oral glucose tolerance test; FI: fasting insulin; FG/FI: fasting glucose to fasting insulin ratio; 
hs‑CRP: high sensitivity C‑reactive protein; HOMA‑IR: homeostasis model assessment of insulin resistance. Data presented are mean±standard deviation. Data for TT, LH/FSH, FI, 
HOMA‑IR, FG/FI, hs‑CRP, and uric acid were skewed, and are presented as median (interquartile range) and were log‑transformed for analysis. *Unadjusted P‑value by student’s t‑test 
or χ2 test. +Age‑adjusted P‑value by analysis of covariance
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Table 2: Lipid profiles of subjects categorized by BMI
Characteristics Total n=87 Nonobese (<25.0 kg/m2) Obese (≥25.0 kg/m2) P* Age-adjusted P+
TC (mg/dL) 174.49±34.66 168.20±33.34 177.81±34.97 0.219 0.815
TG (mg/dL) 79.90±31.77 70.40±20.23 84.89±35.56 0.042 0.287
HDL‑C (mg/dL) 50.17±16.49 51.83±16.76 49.29±16.43 0.499 0.513
LDL‑C (mg/dL) 108.33±33.19 102.23±32.58 111.54±33.34 0.216 0.697
TC/HDL‑C 3.79±1.34 3.51±1.19 3.93±1.41 0.169 0.451
TG/HDL‑C 1.76±0.90 1.50±0.62 1.91±1.06 0.053 0.209
LDL‑C/HDL‑C 2.42±1.21 2.22±1.11 2.54±1.26 0.236 0.541
TC: total cholesterol; TG: triglyceride; HDL‑C: high‑density lipoprotein‑cholesterol; LDL‑C: low‑density lipoprotein‑cholesterol; TC/HDL‑C: total cholesterol to high‑density lipoprotein‑
cholesterol ratio; TG/HDL‑C: triglyceride to high‑density lipoprotein‑cholesterol; LDL‑C/HDL‑C: low‑density lipoprotein‑cholesterol to high‑density lipoprotein‑cholesterol ratio.Data 
presented are mean±standard deviation. *Unadjusted P‑value by student’s t‑test or χ2 test. +Age‑adjusted P‑value by analysis of covariance
Table 3: Comparison of areas under the ROC curves (95%) for potential markers of insulin resistance (HOMA-IR ≥ 2) of subjects 
categorized by BMI
Characteristics Total AUC (95% CI)
Nonobese (<25.0 kg/m2) Obese (≥25.0 kg/m2)
n=87 P n=30 P n=57 P
TC (mg/dL) 0.602 (0.470‑0.735) 0.121 0.687(0.487‑0.886) 0.093 0.561 (0.386‑0.735) 0.466
TG (mg/dL) 0.535 (0.397‑0.673) 0.598 0.569 (0.338‑0.801) 0.533 0.540 (0.364‑0.716) 0.631
LDL‑C (mg/dL) 0.555 (0.421‑0.688) 0.407 0.593 (0.377‑0.81) 0.401 0.528 (0.351‑0.706) 0.731
HDL‑C (mg/dL) 0.516 (0.383‑0.648) 0.811 0.648 (0.423‑0.874) 0.182 0.434 (0.274‑0.595) 0.430
hs‑CRP (mg/dL) 0.582 (0.449‑0.715) 0.216 0.608 (0.373‑0.842) 0.333 0.594 (0.430‑0.758) 0.257
TC/HDL‑C 0.504 (0.366‑0.642) 0.953 0.423 (0.192‑0.655) 0.491 0.558 (0.389‑0.728) 0.482
TG/HDLC 0.504 (0.384‑0.652) 0.787 0.423 (0.192‑0.655) 0.461 0.570 (0.409‑0.731) 0.400
LDL‑C/HDL‑C 0.506 (0.367‑0.644) 0.932 0.435 (0.204‑0.667) 0.561 0.561 (0.390‑0.732) 0.460
ROC: receiver operating characteristics; CI: confidence interval; AUC: area under ROC curve; TC: total cholesterol; TG: triglyceride; HDL‑C: high‑density lipoprotein cholesterol; 
LDL‑C: low‑density lipoprotein cholesterol; hs‑CRP: high sensitivity C‑reactive protein; TC/HDLC: total cholesterol to high‑density lipoprotein‑cholesterol ratio; TG/HDLC: triglyceride 
to high‑density lipoprotein‑cholesterol ratio; LDLC/HDLC: low‑density lipoprotein‑cholesterol to high‑density lipoprotein‑cholesterol ratio; HOMA‑IR: homeostasis model assessment of 
insulin resistance. Data for LDL‑C, TG were skewed and log‑transformed for analysis
Figure 1: (a) Receiver operating characteristics (ROC) curves. Sensitivity represents the true‑positive results, and 1‑specificity represents the false‑positive 
results. The best markers have ROC curves that are shifted to the left with areas under the curve near unity. Non‑diagnostic markers are represented by 
diagnosis with areas under the ROC curves close to 0.5. (b) Receiver operating characteristics (ROC) curves. Sensitivity represents the true‑positive results, 
and 1‑specificity represents the false‑positive results. The best markers have ROC curves that are shifted to the left with areas under the curve near 
unity. Non‑diagnostic markers are represented by diagnosis with areas under the ROC curves close to 0.5. BMI, body mass index; hs_CRP, high sensitivity 
C‑reactive protein; TC, total cholesterol; TG, triglycerides; HDL‑C, high‑density lipoprotein‑cholesterol; LDL‑C, low‑density lipoprotein‑cholesterol; TCHDLC, 
total cholesterol to high‑density lipoprotein‑cholesterol ratio; TGHDLC, triglyceride to high‑density lipoprotein‑cholesterol ratio; LDLC_HDLC, low‑density 
lipoprotein‑cholesterol to high‑density lipoprotein‑cholesterol ratio
ba
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confounding variables on HOMA-IR [Table 4], it revealed that 
among nonobese PCOS women, BMI, MABP, TC, and hs-CRP 
had positive impacts of which no variable showed any 
significance. Similarly, among obese PCOS women, BMI, TC, 
TG, and hs-CRP had no statistically significant positive impact 
on HOMA-IR. The joint effect of the independent variables 
in nonobese (β =0.290, P = 0.538) and obese (β =0.225, 
P = 0.171) women was not significant in predicting HOMA-IR.
The characteristic cutoff points of TG and TG/HDL-C for 
verifying IR are shown in Tables 5a and 5b, respectively. 
In	 nonobese	women,	 TG	of	≥	73.5	was	 the	 cutoff	 point	
for	 predicting	 IR	 (HOMA‑IR	≥	2)	while	 in	 obese	women,	
TG	of	≥	92.5	was	the	cut‑off	point	of	IR.	In	nonobese	and	
obese women [Table 5a], the LR summarized the information 
contained in sensitivity and specificity. In nonobese women, 
the positive LR value reveals that the odds of IR were 
increased 0.73-fold if TG was 73.5 or more. In obese women, 
the positive LR value demonstrates that the odds of IR were 
increased 1.19-fold if the value of TG was 92.5 or more. In the 
case of nonobese women, the negative LR showed increased 
odds of IR when the value of TG was lower than the cut-off 
Table 4: Multiple linear regression analysis and the correlation 
between various factors and HOMA-IR of subjects categorized 
by BMI
Variables β (P)






Age (years) −0.136 (0.294) −0.183 (0.547) −0.206 (0.15)
BMI (Kg/m) −0.10 (0.461) 0.249 (0.267) 0.308 (0.06)
SBP (mmHg) −0.182 (0.424) −0.95 (0.799) −0.161 (0.579)
MABP (mmHg) 0.137 (0.557) 0.244 (0.422) −0.088 (0.773)
TC (mg/dL) 0.476 (0.157) 0.606 (0.413) 0.147 (0.717)
TG (mg/dL) 0.055 (0.682) −0.059 (0.795) 0.220 (0.211)
HDLC (mg/dL) −0.243 (0.512) −0.050 (0.955) −0.28 (0.949)
hs‑CRP (mg/L) 0.228 (0.061) 0.245 (0.354) 0.044 (0.750)
LDLC/HDLC ratio −0.381 (0.376) −0.492 (0.597) −0.101 (0.844)
R2 0.123 (0.307) 0.29 (0.538) 0.225 (0.171)
BMI: body mass index; SBP: systolic blood pressure; MABP: mean arterial blood 
pressure; TC: total cholesterol; TG: triglyceride; HDL‑C: high‑density lipoprotein‑
cholesterol; LDL‑C/HDL‑C ratio: low‑density lipoprotein‑cholesterol to high‑density 
lipoprotein‑cholesterol; hs‑CRP: high sensitivity C‑reactive protein; HOMA‑
IR: homeostasis model assessment of insulin resistance
Table 5a: Comparison of triglycerides for predicting insulin resistance (HOMA-IR ≥ 2.0) of subjects categorized by BMI
Characteristics cutoff point HOMA-IR Sensitivity Specificity Positive LR Negative LR Accuracy (%)
<2.0, n ≥2.0 n
BMI <25.0 (kg/m2) 19 11
0.46 0.37 0.73 1.46 0.57TG <73.5 (mg/dL) 12 6
TG ≥73.5 (mg/dL) 7 5
BMI ≥25.0 (kg/m2) 39 18
0.56 0.53 1.19 0.83 0.51TG <92.5 (mg/dL) 19 8
TG ≥92.5 (mg/dL) 20 10
HOMA‑IR: homeostasis model assessment of insulin resistance; LR: likelihood ratio; BMI: body mass index; TG: triglyceride
Table 5b: Comparison of triglycerides-HDL-C ratio for predicting insulin resistance (HOMA-IR ≥ 2.0) of subjects categorized by BMI
Characteristics cutoff point HOMA-IR Sensitivity Specificity Positive LR Negative LR Accuracy (%)
<2.0, n ≥2.0 n
BMI <25.0 (kg/m2) 19 11
0.36 0.79 1.71 0.81 0.63TG/HDL‑C <1.84 15 7
TG/HDL‑C ≥1.84 4 4
BMI ≥25.0 (kg/m2) 39 18
0.50 0.67 1.19 0.75 0.61TG/HDL‑C <2.0 26 9
TG/HDL‑C ≥2.0 13 9
HOMA‑IR: homeostasis model assessment of insulin resistance; LR: likelihood ratio; BMI: body mass index; TG/HDL‑C: triglyceride/high‑density lipoprotein‑cholesterol ratio
Figure 2: Correlation between TG and HOMA‑IR categorized by BMI. Data for 
HOMAIR was skewed hence log transformed for this analysis. The lines of 
best fit (BMI < 25.0 kg/m2: r2 = 0.014, P > 0.05; BMI ≥ 25.0 kg/m2: r2 = 0.112, 
P < 0.00) are indicated
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points. In the case of obese women, the negative LR revealed 
decreasing odds of IR when the value of TG was lower than 
the cut-off points.
Discussion
The present study evaluated lipid profiles and assessed the 
diagnostic utility of TG and TG/HDL-C ratio as surrogate markers 
in identifying IR in infertile Nigerian PCOS women categorized 
by BMI. The PCOS women in this study were classified as insulin 
resistant	with	HOMA‑IR	of	≥	2.0.[23] HOMA model is widely 
used as a clinical and epidemiological tool since it is more 
cost-effective than the hyperinsulinemic-euglycemic glucose 
clamp. Although the model is less accurate, it showed a strong 
correlation with the glucose clamp method in measuring IR.[24] 
Thus in this study, HOMA-IR was used as the marker for IR. In 
nonobese and obese groups, the PCOS women who are insulin 
resistant were 36.7% and 31.6%, respectively. These percentages 
are higher compared to non-PCOS women categorized by BMI 
reported in the study of Apridonidze et al.[25] In contrast, the 
prevalence of IR reported among Korean obese PCOS women 
by Park et al. was high (66.0%) compared with the obese 
PCOS group in this study. They, however, obtained a lower 
rate (19.9%) in the nonobese PCOS group when compared with 
the present study.[15]
The findings in this study showed there was a good 
correlation between TG and HOMA-IR in the obese group 
which is consistent with the study of Park et al. and Lath 
et al.[15,26] However, the area under the curve (AUC) of TG 
was comparable with those of other potential markers and 
none was an acceptable marker. The ROC curve analysis 
reported by Park et al.[15] differed from our findings. Their 
study revealed that the best cutoff values for TG in identifying 
IR	were	≥	68.5	 in	nonobese	and	≥	100.5	 in	obese	PCOS	
subjects. Furthermore, the present study obtained a positive 
LR of 1.19, which was the largest for TG in obese PCOS 
women, whereas they obtained a positive LR of 2.86, which 
was largest for TG in obese PCOS subjects. Park et al. also 
reported TG and TG/HDL-C as useful markers of IR in Korean 
PCOS patients and the BMI categorized groups.[15] However, 
TG is not a useful marker for predicting IR in nonobese and 
obese PCOS women in this study, although it showed a good 
correlation with HOMA-IR in obese women.
The findings in the present study are consistent with the 
report of Kim-Dorner et al. in which they indicated that TG 
and TG/HDL-C were poor predictors of IR, as measured by 
HOMA-IR, in African Americans, but acceptable markers in 
whites.[17] Their study revealed areas under the ROC curves of 
0.625 and 0.639 for TG and TG/HDL-C respectively in African 
Americans, whereas in this study, we obtained areas under 
the ROC curves of 0.535 and 0.504, respectively. However, 
in whites, TG and TG/HDL-C were acceptable markers for 
IR with areas of 0.763 and 0.770 respectively.[17] After BMI 
categorization in the present study, the areas under the 
ROC curves for TG and TG/HDL-C were 0.569 and 0.423 
respectively in nonobese women, and 0.540 and 0.570, 
respectively, for obese women.
Furthermore, Sumner et al. and Knight et al. reported 
that TG and TG/HDL-C are not reliable as markers of IR in 
African Americans and African descent which is consistent 
with the report in this study.[16,18] Li et al. also reported 
that the association of TG/HDL-C with IR in non-PCOS 
patients was stronger among those with BMI <25 kg/m2 
than	≥30	 kg/m2. Although TG/HDL-C could discriminate 
against IR in nonobese non-PCOS women, it could not in obese 
non-PCOS women.[27] However, McLaughlin et al. showed TG/
HDL-C could discriminate against IR in the subjects with a 
BMI	≥25	kg/m2.[9,10] Despres et al. report also showed that in 
African Americans and white women, lipoprotein lipase (LPL) 
activity which is responsible for clearing TG-containing 
lipoproteins from the circulation, was higher and this might 
induce lower TG levels, further causing a weak association 
between TG levels and IR in those population.[28] It should 
be noted that various study designs, races, age range, and 
adiposity state of the subjects could result in different 
findings, hence, these unavoidable different results.[7,29]
This is the first study reporting on a surrogate marker for 
IR among infertile women with PCOS in our region. Further 
research work will be necessary for finding a suitable 
surrogate marker that would benefit developing countries 
since the cost and availability of insulin assay is a major 
limiting factor for the assessment of IR. There is still the 
need to recruit a larger population of PCOS women for these 
studies. Additionally, funding for research for possible clinical 
and biological surrogate markers of IR is advocated.
Conclusion
In our population, TG and TG/HDL-C did not discriminate 
against IR in nonobese and obese PCOS women, and as such 
would not be reliable markers of IR. A concerted approach 
in finding surrogate markers of IR would have clinical and 
investigational implications.
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